Advanced search
Publication Cover
Journal of Community Hospital Internal Medicine Perspectives Volume 10, 2020 - Issue 3
Journal homepage
9,784
Views
1
CrossRef citations to date
0
Altmetric
Review Article

Diagnosis and management of tumor lysis syndrome.

Isha Puria Department of Hospital Medicine, Lahey Hospital and Medical Center, Burlington, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0982-9785
ORCID Icon,
Deep Sharmab Department of Medicine (Nephrology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA
,
Krishna S. Gunturuc Department of Hematology and Oncology, Lahey Hospital and Medical Center, Burlington, MA, USA
&
Andaleeb A. Ahmedd Department of Anesthesiology and Perioperative Medicine, Tufts School of Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA
Pages 269-272 | Received 17 Feb 2020, Accepted 15 Apr 2020, Published online: 14 Jun 2020

References

  • Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
  • Howard SC, Jones DP, Pui CH. The tumor lysis syndrome [published correction appears in N Engl J Med. 2018 Sep 13;379(11):1094]. N Engl J Med. 2011;364(19):1844–1854.
  • Brown RB, Razzaque MS. Phosphate toxicity and tumorigenesis. Biochim Biophys Acta Rev Cancer. 2018;1869(2):303–309.
  • Lopez-Olivo MA, Pratt G, Palla SL, et al. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(3):481–492.
  • Cairo MS, Coiffier B, Reiter A, et al., TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–586. .
  • Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review [published correction appears in J Clin Oncol. 2010 Feb 1;28(4):708]. J Clin Oncol. 2008;26(16):2767–2778.
  • Jones GL, Will A, Jackson GH, et al. British committee for standards in haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British committee for standards in haematology. Br J Haematol. 2015;169(5):661–671.
  • Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–S19.
  • Van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol. 2004;15(1):175–176.
  • LaRosa C, McMullen L, Bakdash S, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol. 2007;22(1):132–135. .
  • Bose P, Qubaiah O. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther. 2011;36(3):299–326.
  • Sonbol MB, Yadav H, Vaidya R, et al. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol. 2013;88(2):152–154.
  • Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275–279.
  • Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22–34.
  • Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol. 2014;26(2):162–168.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.